Linked Life Data

2548560

Source:http://linkedlifedata.com/resource/pubmed/id/2548560

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1989-9-29
pubmed:abstractText
For the first time in a clinical study oral Ifosfamide was used: 65 elderly or unfit patients with small cell lung cancer (SCLC) were treated as outpatients with fractionated oral Ifosfamide and Etoposide. Forty patients (62%) had extensive stage (ED) disease. The median age of the patients was 66 years. In the 60 patients evaluable for response the objective response rate was 90% with a complete response (CR) rate of 32% and a partial response (PR) rate of 58%. The overall median survival of all 65 patients was 11 months (13 months for LD, 9.5 months for ED). In those patients with LD achieving a CR or a PR radiotherapy was given to the mediastinum. No prophylactic cranial irradiation was given. There was a rapid improvement in the responding patients' performance status and symptoms generally with the first treatment cycle. Overall haematological toxicity was mild, with intravenous antibiotics only being required in 4% of the courses and with only one treatment-related death from septicaemia. A higher than expected rate of CNS toxicity was seen (30%). This was generally mild and always fully reversible and consisted mainly of forgetfulness, occasionally hallucinations, nightmares and somnolence. In only one case did encephalopathy necessitate early termination of treatment. This raises the question of whether Ifosfamide metabolism differs quantitatively or qualitatively when given by the oral route as opposed to the usual intravenous route. We conclude that this simple outpatient based treatment gives a high response rate with rapid improvement in symptoms.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-2822217, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-2833397, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-2837303, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-2985256, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3020704, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3026969, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-348319, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3731096, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3742706, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3754487, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3802382, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-3896483, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-6327578, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-6432305, http://linkedlifedata.com/resource/pubmed/commentcorrection/2548560-6819957
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
258-61
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
pubmed:affiliation
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't